-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 WfmE5s/CGC/JcNCNma3zS/kTYYQkfwRQu9LrPJcLzrHn1f6PgkINvXcFFHvJwCiP
 jYASu9QDMMVAk45aJu6atw==

<SEC-DOCUMENT>0000950123-10-085706.txt : 20100913
<SEC-HEADER>0000950123-10-085706.hdr.sgml : 20100913
<ACCEPTANCE-DATETIME>20100913163036
ACCESSION NUMBER:		0000950123-10-085706
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20100913
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100913
DATE AS OF CHANGE:		20100913

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		101069438

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c05922e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT
style="font-size: 12pt">Washington, D.C. 20549 </FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest event reported): September 13,
2010</B>

<P style="font-size: 24pt" align="center"><B>CYCLACEL PHARMACEUTICALS, INC.<BR>
</B><FONT
style="font-size: 10pt">(Exact name of registrant as specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0" cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>0-50626</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>91-1707622</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0" cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>200 Connell Drive, Suite 1500<BR>
Berkeley Heights, NJ
<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>07922</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number, including area code: <B>(908)
517-7330</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0" cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT face="Wingdings">o</FONT>
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))<BR>
<BR>
<FONT face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<DIV style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="justify"><B>Item&nbsp;8.01 Other Events</B>

<P style="font-size: 10pt; text-indent: 4%" align="justify">On September&nbsp;13, 2010, Cyclacel Pharmaceuticals,
Inc. (the &#8220;<B>Company</B>&#8221;) issued a press release announcing that it has reached agreement with the
U.S. Food and Drug Administration regarding a Special Protocol Assessment on the design of a pivotal Phase 3 trial
for the Company&#8217;s sapacitabine oral capsules as a front-line treatment in elderly patients aged
70&nbsp;years or older with newly diagnosed acute myeloid leukemia who are not candidates for intensive induction
chemotherapy. A copy of the press release is attached as Exhibit&nbsp;99.1.

<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">

 <TR style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000" valign="top">
  <TD nowrap align="left" width="3%"><B>Item&nbsp;9.01</B></TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify"><B>Financial Statements and Exhibits</B></DIV>
</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">

 <TR style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000" valign="top">
  <TD nowrap align="left" width="3%">(d)</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">The following exhibit is furnished with this Report:</DIV>
</TD>
 </TR>

</TABLE>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="8%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="87%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">Exhibit&nbsp;No. </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Description</TD>
 </TR>
 <TR style="font-size: 1px">
  <TD style="border-top: #000000 1px solid" valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD style="border-top: #000000 1px solid" valign="top" nowrap align="left">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press Release dated September&nbsp;13, 2010</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="font-size: 10pt; text-indent: 4%" align="justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.

<P style="font-size: 10pt; text-indent: 48%" align="left"><B>CYCLACEL PHARMACEUTICALS, INC.</B>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="48%">&nbsp;</TD>
  <TD width="4%">&nbsp;</TD>
  <TD width="48%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">By: </TD>
  <TD valign="top" align="left">/s/ Paul McBarron</TD>
 </TR>
 <TR style="font-size: 1px">
  <TD valign="top"><DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV></TD>
  <TD>&nbsp;</TD>
  <TD style="border-top: #000000 1px solid" valign="top" align="left">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top"><DIV style="margin-left: 0px; text-indent: 0px"></DIV></TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Name: Paul McBarron<BR>
Title: Executive Vice President&#8212;Finance,<BR>
Chief Financial
Officer and Chief Operating Officer</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="justify">Date: September&nbsp;13, 2010

<P style="font-size: 10pt" align="right">&nbsp;

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c05922exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Helvetica',Arial,sans-serif">

<P style="font-size: 10pt" align="right"><B>Exhibit&nbsp;99.1</B>

<P style="font-size: 10pt" align="center"><B>PRESS RELEASE<BR><BR>
CYCLACEL PHARMACEUTICALS REACHES AGREEMENT WITH FDA<BR>
ON A SPECIAL
PROTOCOL ASSESSMENT FOR PIVOTAL PHASE 3 TRIAL OF SAPACITABINE IN AML</B>

<P style="font-size: 10pt" align="justify"><B>BERKELEY HEIGHTS, NJ &#8211; September&nbsp;13, 2010 &#8211;
</B>Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company developing oral
therapies that target the various phases of cell cycle control for the treatment of cancer and other serious
diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration
(FDA)&nbsp;regarding a Special Protocol Assessment (SPA)&nbsp;on the design of a pivotal Phase 3 trial for the
Company&#8217;s sapacitabine oral capsules as a front-line treatment in elderly patients aged 70&nbsp;years or
older with newly diagnosed acute myeloid leukemia (AML)&nbsp;who are not candidates for intensive induction
chemotherapy.

<P style="font-size: 10pt" align="justify">&#8220;The SPA agreement with FDA represents an important milestone for
Cyclacel and provides a clear registration pathway for sapacitabine,&#8221; said Spiro Rombotis, President and
Chief Executive Officer of Cyclacel. &#8220;If it reaches the market, sapacitabine would be the first
orally-administered drug to be offered to this patient population with the potential to serve as induction,
consolidation and maintenance treatment of this life-threatening disease. In addition to progressing to Phase 3 in
AML, we look forward to reporting sapacitabine Phase 2 data in myelodysplastic syndromes (MDS)&nbsp;and non-small
cell lung cancer (NSCLC).&#8221;

<P style="font-size: 10pt" align="justify">The Phase 3, registration-directed, clinical trial of sapacitabine oral
capsules to be conducted under the SPA will be a randomized study against an active control drug with the primary
objective of demonstrating an improvement in overall survival. Sapacitabine will be administered as an outpatient
treatment. Cyclacel plans to begin patient enrollment in this Phase 3 trial before the end of 2010. Additional
information on the design of the trial will be provided after initiation of the study.

<P style="font-size: 10pt" align="justify">&#8220;We are pleased to receive the SPA Agreement letter from the FDA
stating that the design and planned analysis of the pivotal Phase 3 study adequately address the objectives
necessary to support the submission of a New Drug Application (NDA),&#8221; said Judy Chiao, M.D., Vice President
of Clinical Development and Regulatory Affairs of Cyclacel. &#8220;AML in the elderly is a life-threatening
disease with high unmet medical need. Patients with AML aged 70&nbsp;years or older have a poor prognosis as the
majority of these patients are not candidates for intensive induction chemotherapy because of poor tolerability to
such therapy and a high risk of relapse because of the lack of effective consolidation and maintenance therapy. We
will now concentrate our efforts on initiating the Phase 3 study in AML in collaboration with our clinical
investigators.&#8221;

<P style="font-size: 10pt" align="justify">In addition to the Cyclacel-sponsored trials of sapacitabine, the
company has been approached by cooperative groups seeking to conduct, largely at their expense,
investigator-initiated studies of sapacitabine with alternative study designs.

<P style="font-size: 10pt" align="justify"><B>About Acute Myeloid Leukemia (AML)</B>

<P style="font-size: 10pt" align="justify">AML is a cancer of the blood cells that progresses rapidly and if not
treated, could be fatal in a few months. AML is generally a disease of older people and is uncommon before the age
of 40. The average age of a patient with AML is about 67&nbsp;years. There are more than 12,300 new cases of AML,
of which about half are elderly, and nearly 9,000 deaths caused by this cancer each year in the United States. A
recently published review of The University of Texas M. D. Anderson Cancer Center&#8217;s historical experience
with front-line intensive induction chemotherapy for elderly AML patients aged 70&nbsp;years or older demonstrated
that while 45% of patients achieved a complete remission, median overall survival
was only 4.6&nbsp;months and 36% of patients died within the first 8&nbsp;weeks of treatment, underscoring the
unmet need in this patient setting. &#8224;

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">4
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Helvetica',Arial,sans-serif">


<P style="font-size: 10pt" align="justify"><B>About Special Protocol Assessment (SPA)</B>

<P style="font-size: 10pt" align="justify">A Special Protocol Assessment is a binding written agreement with the
FDA that the sponsor&#8217;s proposed trial protocol design, clinical endpoints and statistical analyses are
acceptable to support regulatory approval. Final marketing approval depends on efficacy results, adverse event
profile and an evaluation of the benefit/risk of a treatment as demonstrated in the trial. For further information
regarding the SPA process, please visit the FDA website, <U>www.fda.gov</U>.

<P style="font-size: 10pt" align="justify"><B>About sapacitabine</B>

<P style="font-size: 10pt" align="justify">Sapacitabine (CYC682), an orally-available nucleoside analogue, is
currently being evaluated in Phase 2 trials in patients with hematological malignancies and solid tumors.
Sapacitabine acts through a dual mechanism, interfering with DNA synthesis by causing single-strand DNA breaks and
inducing arrest of cell cycle progression mainly at G2-Phase. Both sapacitabine and CNDAC, its major metabolite,
have demonstrated potent anti-tumor activity in preclinical studies. Over 200 patients have received sapacitabine
in Phase 2 studies in AML, MDS, cutaneous T cell lymphoma (CTCL)&nbsp;and non-small cell lung cancer (NSCLC).
Sapacitabine has been administered to approximately 170 patients in five Phase 1 studies with both hematologic
malignancies and solid tumors. In December&nbsp;2009 at the 51st Annual Meeting of the American Society of
Hematology (ASH), Cyclacel reported data from a randomized Phase 2 study including promising 1-year survival in
elderly patients with AML aged 70&nbsp;years or older. Sapacitabine is part of Cyclacel&#8217;s pipeline of small
molecule drugs designed to target and stop uncontrolled cell division.

<P style="font-size: 10pt" align="justify"><B>About Cyclacel Pharmaceuticals, Inc.</B>

<P style="font-size: 10pt" align="justify">Cyclacel is a biopharmaceutical company developing oral therapies that
target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Three
product candidates are in clinical development: Sapacitabine (CYC682), a cell cycle modulating nucleoside analog,
completed Phase 2 studies for the treatment of acute myeloid leukemia in the elderly and is in Phase 2 for
myelodysplastic syndromes and lung cancer. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase)
inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial
in combination with sapacitabine. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients
with solid tumors. Cyclacel&#8217;s ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair&#174;
Cream for radiation dermatitis, Numoisyn&#174; Liquid and Numoisyn&#174; Lozenges for xerostomia. Cyclacel&#8217;s
strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a
portfolio of commercial products and a development pipeline of novel drug candidates. For additional information
please visit <U>www.cyclacel.com</U>.

<P style="font-size: 10pt" align="justify"><B>Forward-looking Statements</B>

<P style="font-size: 10pt" align="justify">This news release contains certain forward-looking statements that
involve risks and uncertainties that could cause actual results to be materially different from historical results
or from any future results expressed or implied by such forward-looking statements. Such forward-looking
statements include statements regarding, among other things, the efficacy, safety, and intended utilization of
Cyclacel&#8217;s product candidates, the conduct and results of future clinical trials, plans regarding regulatory
filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause
actual results to differ materially include the risk that product candidates that appeared promising in early
research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials,
the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on
outside financing to meet capital

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">5
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Helvetica',Arial,sans-serif">

<P style="font-size: 10pt" align="justify">requirements, and the risks associated with reliance on collaborative
partners for further clinical trials, development and commercialization of product candidates. You are urged to
consider statements that include the words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221;
&#8220;could,&#8221; &#8220;should,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221;
&#8220;projects,&#8221; &#8220;potential,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221;
&#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;continues,&#8221; &#8220;forecast,&#8221;
&#8220;designed,&#8221; &#8220;goal,&#8221; or the negative of those words or other comparable words to be
uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company
faces, please refer to our most recent Annual Report on Form 10-K and other periodic and current filings that have
been filed with the Securities and Exchange Commission and are available at <U>www.sec.gov</U>. Such
forward-looking statements are current only as of the date they are made, and we assume no obligation to update
any forward-looking statements, whether as a result of new information, future events or otherwise.

<P style="font-size: 10pt" align="justify"><B>Contact for Cyclacel Pharmaceuticals, Inc.</B>

<P style="font-size: 10pt" align="justify">Investors/Media: <BR>
Corey Sohmer, (908)&nbsp;517-7330
<BR>
<U>csohmer@cyclacel.com</U>

<P style="font-size: 10pt" align="justify">&#8224; <I>Blood First Edition Paper, prepublished online July&nbsp;28,
2010; DOI 10.1182/blood-2010-03-276485
(</I><U><I>http://bloodjournal.hematologylibrary.org/cgi/content/abstract/blood-2010-03-276485v1</I></U><I>).</I>

<P style="font-size: 10pt" align="justify">&#169; Copyright 2010 Cyclacel Pharmaceuticals, Inc. All Rights
Reserved. The Cyclacel logo and Cyclacel&#174; are trademarks of Cyclacel Pharmaceuticals, Inc. Numoisyn&#174; and
Xclair&#174; are trademarks of Sinclair Pharma plc.

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">6
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
